Joseph Ware Email & Phone Number

South San Francisco, Ca, Us

Sevenoaks, Gb

Agile drug development focusing on translating scientific data into knowledge to deliver novel modalities to patients w/unmet medical needs.

Clinical Pharmacologist with extensive expertise in novel biology, oncology, neurodegenerative drug development of small molecules,ADCs, SMDCs, mAb/bsAbs, and cross functional strategy.

Bothell, Washington, Us

Palo Alto, California, Us

South San Francisco, California, Us

Oss, Nl

South San Francisco, California, Us

Formulation of Clinical pharmacology strategy of small molecule oncology drug candidates in early clinical development: ‘real time’ PK to support dose escalation decisions, phase I and phase Ib combination and dose escalation strategies, phase II and III oncology planning to optimally characterize PK and PD relationship to improve patient selection, efficacy and tolerability. Utilize totality of data to recommend dose/regimens for New Molecular Entities (NMEs) in all stages of Drug Development either as single agent or combination standard-of care therapy and/or NMEs, planning for formulation bridging strategies, and assessment of drug-drug interaction (DDI) risk in both healthy volunteers and cancer patients. Partner with Early Clinical Development (Oncology), translational oncology, Safety Assessment, biostatistics, DMPK, oncology diagnostics & biomarkers, clinical operations, and clinical Safety to achieve optimal study design, analysis plans, bridge preclinical to Clinical PK/PD, enable Clinical Pharmacology plan, support NME regulatory filings and represent Clinical Pharmacology at program team, cross-functional leadership reviews.Support MEK, IAP, PI3K and PI3K/mTOR projects leading to NME or NME/NME trials in gRED Oncology. Responsible for IND, IB and regulatory responses, assess DDI potential, development of exposure-response relationships (efficacy/safety), formulation bridging strategy, PGx-PK evaluation, and global bridging strategy. Contribute to the International Transporter Consortium (2006-present), NIH Principles of Clinical Pharmacology (2008-present), CPLQ member (2011-present), and establish a cross-functional working group to investigate sources(s) of PK variability related to the oral absorption molecular targeted agents (2010-present).

New York, New York, Us

Pfizer Ann Arbor Department of Pharmacokinetics, Dynamics and Metabolism to support early drug discovery to optimize the early ADME properties for CNS and anti-inflammatory discovery programs to include: identification of an in-vitro/in-vivo relationship of pharmacokinetics, hit-to lead support, define concentration or exposure response pharmacodynamic (PD); identification of reactive metabolite liability, strategy to reduce drug attrition risk related to drug-induced rash and drug-induced liver injury. Utilized knowledge of drug disposition and transporter biology to enable drug discovery and led successful laboratory effort to characterize the role of drug transporters in PK. Worked to build and maintain collaborations with multiple universities throughout North America, Europe, and Japan. Moreover, worked closely with Scientists at the NCI to evaluate the interaction of curcumin with drug transport substrates.Great Lakes Drug Metabolism Discussion Group (2006-present)

New York, New York, Us

Drug Metabolism and Pharmacokinetics at the Pharmacia Corporation in Kalamazoo, MI. Responsible for human and non-clinical [14C]-radiolabel studies for sumanirole (PNU-95666) and sonepiprazole (PNU-101387)Responsible for phase II drug transport DDI strategy for Edotecarin and phase IV oral camptosar-drug/life-cycle mangagement strategy.Utilize in vitro drug metabolism data and known pathways of drug clearance, identified key ADME liability leading to a single ‘worst-case scenario’ DDI study.Implementation and development of novel in vitro and in vivo techniques to study drug-drug and drug-transporter interactions to context pharmaceutically-important uptake and efflux systems in the small intestine, liver, kidney, and at the blood-brain barrier (1999 to 2007).

Bethesda, Md, Us

IRTA post-doctoral fellow in the Laboratory of Molecular and Cellular Toxicology directed by Dr. Lance Pohl of the NHLBI. Investigated the role of oral tolerance as a mechanism to prevent idiosyncratic adverse drug reactions. During my fellowship with Dr. Pohl, I gained experience in the development of animal models of drug-induced toxicity, mucosal immunology and characterization of drug-protein adducts. Moreover, while at the NHLBI, I was able to study the influence of cyclooxygenase inhibition on electrolyte transport in the kidney with Dr. Mark Knepper of the Laboratory of Kidney and Electrolyte Metabolism. Both experiences at the NHLBI helped to provide a strong foundation to build multidisciplinary approaches to better understand host determinants of drug action and toxicity.